Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen.
The influence of chronic and acute exposure to parathyroid hormone (PTH) on formation and breakdown of type I collagen, using two recently developed radioimmunoassays for serum PICP (the carboxyterminal propeptide of type I procollagen) and serum ICTP (the carboxyterminal telopeptide of type I collagen), have been evaluated. Fasting morning values were obtained from 18 women with primary hyperparathyroidism (HPT) and an equal number of age-matched, healthy controls. A 24-hour infusion of synthetic human parathyroid hormone (PTH 1-38) was performed in 14 healthy females. The patients with HPT had higher values for serum ICTP than the controls (6.0 +/- 3.0 and 4.1 +/- 2.1 micrograms/liter; P < 0.05), whereas the serum PICP concentrations were not different (170 +/- 72 and 151 +/- 65 micrograms/liter; n.s.). During infusion of PTH in healthy subjects, there was an increase of the serum ICTP concentrations (from 3.6 +/- 1.3 to 4.4 +/- 1.8 micrograms/liter; P < 0.001) whereas those of serum PICP decreased (from 185 +/- 78 to 118 +/- 42 micrograms/liter; P < or = 0.0001). The increase of serum ICTP during infusion of PTH was positively related to the increase of serum calcium and other indices of bone resorption, i.e., fasting urinary excretions of hydroxyproline and calcium. The decrease of serum PICP was also related to the changes of serum ICTP and hydroxyproline in urine, serum calcium, and alkaline phosphatase but not to osteocalcin, an established marker of osteoblastic activity. The findings support the fact that serum ICTP is a valuable method for evaluating bone resorption and is also easy to perform.(ABSTRACT TRUNCATED AT 250 WORDS)
Brahm
H
H
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Ljunggren
O
O
Larsson
K
K
Lindh
E
E
Ljunghall
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D001862:Bone Resorption / Q000097:blood / Q000652:urine; D002118:Calcium / Q000097:blood / Q000652:urine; D003094:Collagen / Q000096:biosynthesis* / Q000378:metabolism; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006961:Hyperparathyroidism / Q000378:metabolism*; D007262:Infusions, Intravenous; D008875:Middle Aged; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D011347:Procollagen / Q000097:blood; D011863:Radioimmunoassay
D010281:Parathyroid Hormone; D010446:Peptide Fragments; D011347:Procollagen; C035747:parathyroid hormone (1-38); C042813:procollagen type I carboxy terminal peptide; D015675:Osteocalcin; D003094:Collagen; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium